Strong first quarter for Foxway with accelerated growth and improved margins

Q1 2026 net sales rose 25.8% to SEK 2,171.1 million, with organic growth of 32.3% in constant currency. Adjusted EBITDA increased to SEK 193.5 million from SEK 140.3 million, and EBIT turned positive at SEK 52.9 million versus a loss of SEK 4.1 million a year earlier. The results show strong top-line momentum and improving profitability, supported by a 3.6% adjusted operational EBITDA margin.

Analysis

This print suggests a business whose revenue acceleration is no longer just a top-line story; the inflection is broad enough to push operating leverage through the P&L despite presumably still-elevated reinvestment. The key second-order implication is that fixed-cost absorption is now doing real work, which typically creates a lagged rerating opportunity because the market initially prices the sales beat but underestimates how quickly incremental margins can expand over the next 2-3 quarters.

The quality of the beat matters more than the magnitude: when adjusted operational EBITDA grows materially faster than sales, it usually indicates either better mix, stronger pricing power, or a transition from growth-at-all-costs toward a more disciplined operating model. That tends to pressure smaller rivals that cannot match both scale and margin expansion, especially if they are funding growth with promotional spend or higher working capital. Over the next 6-12 months, the competitive gap can widen if this company sustains even half of the current organic growth rate, because competitors are forced to choose between share loss and margin erosion.

The main risk is that this is a pull-forward rather than a durable demand step-up. If the growth is tied to one-off channel restocking, seasonal strength, or unusually easy comparables, the market could quickly compress the multiple once the next two quarters normalize. The reversal signal to watch is not revenue growth alone but whether operating profit continues to improve on a sequential basis; if margins stall while sales stay high, sentiment can flip within weeks.

Consensus may be underappreciating how much of the upside is optionality on profitability rather than revenue. In this setup, the equity often has asymmetric upside if management can prove that current growth is self-funded and repeatable, because the rerating comes from both higher near-term estimates and a lower implied cost of capital. The contrarian risk is that investors extrapolate 32% organic growth too far; if that decelerates sharply, the stock can give back most of the post-earnings move even if absolute profitability remains positive.

Key Decisions for Investors

• Go long on any listed peer with a similar growth profile but weaker margin trajectory versus this company; favor a relative-value pair that shorts the higher-burn competitor over the next 1-2 quarters if valuation has already rerated on revenue alone.
• Add to long exposure on the next 3-5% pullback rather than chasing strength; the better entry is after the market digests whether growth is repeatable, which usually shows up in the first post-print revisions cycle.
• If the stock is liquid enough, buy 2-3 month call spreads to capture estimate revisions while defining downside; target a 2:1 to 3:1 payoff if the market begins to price sustained margin expansion.
• Set a tactical stop if the next monthly/quarterly operating metric shows sequential deceleration of more than 20% in organic growth or flat adjusted operational EBITDA margin; that would signal the thesis is moving from operating leverage to transitory demand.